Regenxbio Inc (RGNX) Stock Price, Quote & News

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phas...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 552 8181

Website: www.regenxbio.com

Address:

9804 Medical Center Drive, Rockville, United States

They_Call_Me_Tater_Salad Oct. 23 at 10:14 PM

$RGNX Great two months. Very optimistic about the next 6-12.

0 · Reply

SmartMoneyTradez Oct. 22 at 1:51 PM

$RGNX Bought the dip. 2-3 week hold $NRXP $BCRX Added for a one month hold. 🛑 loss in place

0 · Reply

waugusti Oct. 22 at 12:19 PM

$RGNX i guess the rgnx story ends in 2026 with a buyout by abbvie.

1 · Reply

WaveRB77 Oct. 22 at 3:37 AM

$RGNX been 6 longyears i clinical trials.The ship gaining speed!!!!!Upon approval in early 26 stock hits $30.00.BY 2028 this stock is $70 dollars a share!!!

0 · Reply

Quantumup Oct. 21 at 2:34 PM

RBC Capital reiterated $FDMT Outperform-$26, and said Boston NDR Strengthens Its Conviction That GTx Will Have a Role in the $15B Retina Market $OCUL $EYPT $REGN KOD $RGNX - ABBV ADVM SNY RBC Capital additionally said:

1 · Reply

Canuckchic Oct. 18 at 3:34 AM

$RGNX nice after hours spike!

0 · Reply

Lanikai16 Oct. 18 at 1:16 AM

$RGNX I compared today’s slides (2 year results) to the one year data release from 11/2023. Key findings: Demonstrated sustained or improved Diabetic Retinopathy Severity Scale (DRSS) response at 2 years. Transitioning to pivotal Phase IIb/III trial for NPDR population.

1 · Reply

maphere Oct. 17 at 9:32 PM

$CLSD $RGNX Here's the presentation slide deck presented today (23 slides) https://www.regenxbio.com/getmedia/7963aa56-bd54-47ae-afbb-9dffff943801/Wykoff_Sura-vec_SCS-ALTITUDE_AAO-2025_FINAL_v1b-12.pdf?ext=.pdf Slidedeck from Aug. 25th (13 slides) https://ir.regenxbio.com/static-files/ec4713fe-ca17-4e07-800b-0fd194153a8c

2 · Reply

chivo12 Oct. 17 at 12:24 PM

$RGNX Could be an interesting weekend as it appears that interim ALTITUDE eye data to be shared late this afternoon. I don’t recall any interim data being shared from this study since a presentation at the same annual meeting Friday Nov 3, 2023 when rgnx also issued a PR after the market closed and a con call the following Monday morning. In my opinion, if there is ever to be a parabolic change in the value of this company, it will be driven by this indication/delivery. https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-presentation-american-academy-ophthalmology

2 · Reply

maphere Oct. 16 at 4:20 PM

$RGNX Regenx and Serepta are arguing over a patent... https://fedcircuitblog.com/2025/10/15/argument-recap-regenxbio-inc-v-sarepta-therapeutics-inc/

2 · Reply

REGENXBIO to Participate in Upcoming Investor Conferences

Oct 9, 2025, 7:05 AM EDT - 18 days ago

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

Oct 6, 2025, 7:05 AM EDT - 21 days ago

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

Sep 29, 2025, 7:05 AM EDT - 4 weeks ago

REGENXBIO Announces Presentation at the World Muscle Society

Sep 9, 2025, 6:12 AM EDT - 6 weeks ago

Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome

Sep 8, 2025, 2:05 PM EDT - 6 weeks ago

REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 6, 2025, 8:29 AM EDT - 7 weeks ago

Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome

Sep 5, 2025, 7:05 AM EDT - 7 weeks ago

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

Aug 19, 2025, 12:01 PM EDT - 2 months ago

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

Aug 18, 2025, 5:00 PM EDT - 2 months ago

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

Aug 8, 2025, 9:11 AM EDT - 2 months ago

REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:05 AM EDT - 2 months ago

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

Aug 7, 2025, 7:00 AM EDT - 2 months ago

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

Jul 31, 2025, 7:05 AM EDT - 3 months ago

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

Jul 10, 2025, 11:54 AM EDT - 3 months ago

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Jun 6, 2025, 4:02 PM EDT - 5 months ago

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

Jun 5, 2025, 11:43 AM EDT - 5 months ago

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

Jun 5, 2025, 7:05 AM EDT - 5 months ago

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Jun 2, 2025, 7:05 AM EDT - 5 months ago

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

May 19, 2025, 4:05 PM EDT - 5 months ago

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 14, 2025, 7:13 AM EDT - 5 months ago

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

May 13, 2025, 7:07 AM EDT - 5 months ago

REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:05 AM EDT - 5 months ago

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

May 12, 2025, 4:05 PM EDT - 5 months ago

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

May 8, 2025, 7:05 AM EDT - 6 months ago

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

Apr 30, 2025, 4:05 PM EDT - 6 months ago

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

Mar 26, 2025, 12:31 PM EDT - 7 months ago

5 Reasons To Buy Regenxbio Right Now

Mar 19, 2025, 9:15 AM EDT - 7 months ago

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

Mar 13, 2025, 6:44 PM EDT - 8 months ago

REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:05 PM EDT - 8 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

Mar 10, 2025, 7:05 AM EDT - 8 months ago

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 4, 2025, 7:31 AM EST - 8 months ago

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

Feb 26, 2025, 4:05 PM EST - 8 months ago

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Feb 11, 2025, 3:20 PM EST - 9 months ago

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

Jan 30, 2025, 7:05 AM EST - 9 months ago

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

Jan 16, 2025, 4:01 AM EST - 10 months ago

Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026

AMD

Jan 15, 2025, 3:27 PM EST - 10 months ago

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Jan 14, 2025, 5:00 AM EST - 10 months ago

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

Jan 13, 2025, 8:31 AM EST - 10 months ago

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

ABBV

Dec 6, 2024, 6:29 PM EST - 11 months ago

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

AMTM APO CMA CRI CRS HPP KELYA

Nov 18, 2024, 7:05 AM EST - 1 year ago

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

Nov 14, 2024, 7:05 AM EST - 1 year ago

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

Nov 6, 2024, 11:16 PM EST - 1 year ago

REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 1 year ago

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

Oct 31, 2024, 3:38 PM EDT - 1 year ago

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Oct 30, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

Oct 21, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

Oct 18, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

Sep 23, 2024, 4:05 PM EDT - 1 year ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

Sep 17, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

They_Call_Me_Tater_Salad Oct. 23 at 10:14 PM

$RGNX Great two months. Very optimistic about the next 6-12.

0 · Reply

SmartMoneyTradez Oct. 22 at 1:51 PM

$RGNX Bought the dip. 2-3 week hold $NRXP $BCRX Added for a one month hold. 🛑 loss in place

0 · Reply

waugusti Oct. 22 at 12:19 PM

$RGNX i guess the rgnx story ends in 2026 with a buyout by abbvie.

1 · Reply

WaveRB77 Oct. 22 at 3:37 AM

$RGNX been 6 longyears i clinical trials.The ship gaining speed!!!!!Upon approval in early 26 stock hits $30.00.BY 2028 this stock is $70 dollars a share!!!

0 · Reply

Quantumup Oct. 21 at 2:34 PM

1 · Reply

Canuckchic Oct. 18 at 3:34 AM

$RGNX nice after hours spike!

0 · Reply

Lanikai16 Oct. 18 at 1:16 AM

1 · Reply

maphere Oct. 17 at 9:32 PM

2 · Reply

chivo12 Oct. 17 at 12:24 PM

2 · Reply

maphere Oct. 16 at 4:20 PM

$RGNX Regenx and Serepta are arguing over a patent... https://fedcircuitblog.com/2025/10/15/argument-recap-regenxbio-inc-v-sarepta-therapeutics-inc/

2 · Reply

squiggleburp Oct. 15 at 8:55 PM

$RGNX strong like bull. The anticipation is building leading up to Februarys PDUFA!!!

1 · Reply

kaos224 Oct. 15 at 2:04 PM

$RGNX

0 · Reply

USA_toinfinity_andbeyond Oct. 12 at 9:17 PM

$LAC $CRCL $RGNX $ATOS $MNMD I reckon the market will be back to where it was on Thursday. What do you think?

2 · Reply

Tain0os Oct. 10 at 8:38 PM

$SPY $CSPX (Ireland S&P 500) firm long at the EU open tomorrow. Opened Q4 net longs today -> $RGNX $OMER $INVA $AXGN

1 · Reply

Cashmoneyt Oct. 10 at 5:07 PM

$RGNX $RGNX If it drops below $11 I’m buying up more, waiting until Monday. Already got another 100 shares today. This will be $30+ in a year.

0 · Reply

BRITLS Oct. 10 at 4:15 PM

$RGNX rough

1 · Reply

squiggleburp Oct. 10 at 12:52 PM

$RGNX Yesterday was a beautiful thing. This stock has had a Northern trajectory since I bought it. I took a bit of profit. Sorry. $14 incoming!

0 · Reply

_CircuitBreaker Oct. 9 at 11:53 PM

Keep a close watch on CMCT! $NVT $TPET $RGNX $SPIR ×

0 · Reply

WaveRB77 Oct. 9 at 1:03 PM

$RGNX Data on phase2 trial ALTITUDE .This study is looking at the results of RGX314 in suprachroidal delivery.

1 · Reply

Doozio Oct. 9 at 1:31 AM

$RGNX Thursday 🐑 🎁?

0 · Reply

WaveRB77 Oct. 8 at 8:01 PM

$RGNX anybody hear any update???

3 · Reply

DarkOrb Oct. 8 at 5:43 PM

$RGNX Agree. It's trying to break out of a very long base, but we're likely going to need more volume over the next week or two for it to work.

0 · Reply

Market Cap	658.20M
Revenue (ttm)	83.33M
Net Income (ttm)	-227.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-272.53%
Debt to Equity Ratio	0.00

Volume	461,800
Avg Vol	578,412
Day's Range	N/A - N/A
Shares Out	50.51M
Stochastic %K	86%
Beta	1.17
Analysts	Strong Sell
Price Target	$29.27